Profile data is unavailable for this security.
About the company
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
- Revenue in USD (TTM)0.00
- Net income in USD-167.14m
- Incorporated2013
- Employees100.00
- LocationSolid Biosciences Inc500 RUTHERFORD AVENUE, 3RD FLOORCHARLESTOWN 02129United StatesUSA
- Phone+1 (617) 337-4680
- Fax+1 (302) 655-5049
- Websitehttps://www.solidbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alto Neuroscience Inc | 0.00 | -62.26m | 438.35m | 76.00 | -- | 3.44 | -- | -- | -2.31 | -2.31 | 0.00 | 4.11 | 0.00 | -- | -- | 0.00 | -36.77 | -- | -39.46 | -- | -- | -- | -- | -- | -- | -- | 0.1675 | -- | -- | -- | -69.21 | -- | -- | -- |
| Prothena Corporation PLC | 11.79m | -280.46m | 449.48m | 163.00 | -- | 1.52 | -- | 38.14 | -5.21 | -5.21 | 0.219 | 5.48 | 0.0249 | -- | -- | 72,306.75 | -59.18 | -14.95 | -65.99 | -16.06 | -- | -- | -2,379.59 | -89.33 | -- | -- | 0.00 | -- | 47.92 | 178.00 | 16.81 | -- | -11.70 | -- |
| Organogenesis Holdings Inc | 465.22m | -13.39m | 470.84m | 869.00 | -- | 1.85 | 98.34 | 1.01 | -0.1108 | -0.1108 | 3.62 | 3.04 | 0.9731 | 3.56 | 3.45 | 535,348.70 | 0.2102 | 6.65 | 0.2549 | 8.18 | 74.49 | 75.66 | 0.216 | 6.14 | 2.88 | -- | 0.0085 | 0.00 | 11.29 | 13.06 | -118.95 | -- | 9.98 | -- |
| Ginkgo Bioworks Holdings Inc | 180.61m | -339.55m | 479.15m | 834.00 | -- | 0.8448 | -- | 2.65 | -6.22 | -6.22 | 3.31 | 9.85 | 0.1353 | -- | 7.80 | 216,554.00 | -25.43 | -68.97 | -27.83 | -75.53 | 72.71 | 66.73 | -188.00 | -409.12 | -- | -- | 0.00 | -- | -9.71 | 33.18 | 38.73 | -- | 23.00 | -- |
| Lyell Immunopharma Inc | 41.00k | -325.66m | 480.96m | 300.00 | -- | 1.33 | -- | 11,730.81 | -22.26 | -22.26 | 0.0027 | 17.06 | 0.00008 | -- | -- | 136.67 | -63.41 | -28.62 | -67.72 | -30.08 | -- | -- | -794,292.70 | -1,176.84 | -- | -- | 0.00 | -- | -53.08 | -37.83 | -46.18 | -- | 14.67 | -- |
| ADC Therapeutics SA | 75.21m | -166.94m | 484.36m | 263.00 | -- | -- | -- | 6.44 | -1.51 | -1.51 | 0.6852 | -2.11 | 0.2355 | 0.3207 | 3.20 | 285,965.80 | -52.26 | -45.95 | -65.58 | -53.58 | 92.73 | -- | -221.97 | -263.96 | 4.34 | -2.91 | 2.10 | -- | 1.84 | 97.79 | 34.25 | -- | -16.59 | -- |
| Verastem Inc | 13.38m | -241.11m | 484.53m | 78.00 | -- | -- | -- | 36.22 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Solid Biosciences Inc | 0.00 | -167.14m | 485.38m | 100.00 | -- | 2.23 | -- | -- | -2.49 | -2.49 | 0.00 | 2.80 | 0.00 | -- | -- | 0.00 | -68.82 | -47.92 | -78.37 | -53.98 | -- | -- | -- | -2,151.47 | -- | -- | 0.0013 | -- | -- | -- | -29.87 | -- | -31.66 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 502.88m | 72.00 | -- | 3.13 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 70.86m | -68.58m | 515.22m | 103.00 | -- | 3.57 | -- | 7.27 | -0.1894 | -0.1894 | 0.1954 | 0.3307 | 0.2689 | 1.06 | 27.10 | 688,000.00 | -26.02 | -55.75 | -29.23 | -66.32 | 99.41 | 95.36 | -96.77 | -1,103.37 | 5.63 | -6.58 | 0.3199 | -- | 2,481.48 | -37.35 | -13.15 | -- | 71.25 | -- |
| Regenxbio Inc | 161.32m | -177.92m | 519.39m | 353.00 | -- | 3.22 | -- | 3.22 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| ProKidney Corp | 744.00k | -71.03m | 520.44m | 204.00 | -- | -- | -- | 699.52 | -0.5443 | -0.5443 | 0.0057 | -3.41 | 0.0018 | -- | 0.2347 | 3,647.06 | -38.54 | -- | -- | -- | -- | -- | -21,403.63 | -- | -- | -- | 0.0003 | -- | -- | -- | -72.51 | -- | -- | -- |
| Evommune Inc | 3.00m | -66.26m | 525.19m | 45.00 | -- | -- | -- | 175.06 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| Keros Therapeutics Inc | 246.72m | 64.45m | 525.24m | 82.00 | 11.17 | 0.9956 | 7.97 | 2.13 | 1.54 | 1.54 | 6.07 | 17.32 | 0.3732 | -- | 127.17 | 1,459,870.00 | 9.75 | -36.26 | 10.16 | -38.17 | -- | -- | 26.12 | -2,307.89 | -- | -- | 0.00 | -- | 2,250.99 | -18.71 | -22.46 | -- | 48.10 | -- |
| Perspective Therapeutics Inc | 1.08m | -106.31m | 527.42m | 138.00 | -- | 1.42 | -- | 490.63 | -1.46 | -1.46 | 0.0147 | 3.26 | 0.0031 | -- | 5.43 | 7,789.86 | -31.00 | -- | -33.37 | -- | -- | -- | -9,889.68 | -- | -- | -- | 0.0067 | -- | 1.39 | -- | -109.13 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -59.39m | 528.95m | 41.00 | -- | 2.34 | -- | -- | -2.26 | -2.26 | 0.00 | 6.18 | 0.00 | -- | -- | 0.00 | -29.19 | -- | -30.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -285.99 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Solid Biosciences Inc's reporting currency: US Dollar USD
52.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Sep 2025 | 11.83m | 15.19% |
| RA Capital Management LPas of 30 Sep 2025 | 5.81m | 7.46% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 4.06m | 5.21% |
| Adage Capital Management LPas of 30 Sep 2025 | 4.00m | 5.13% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.11m | 3.99% |
| Vestal Point Capital LPas of 30 Sep 2025 | 2.98m | 3.82% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 2.91m | 3.74% |
| Citadel Advisors LLCas of 30 Sep 2025 | 2.54m | 3.27% |
| Redmile Group LLCas of 30 Sep 2025 | 1.90m | 2.44% |
| Nantahala Capital Management LLCas of 30 Sep 2025 | 1.70m | 2.18% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
